Target intelligence / Profile preview

Bone morphogenetic protein receptor type 2 (BMPR2) (BMPR2)

Target
BMPR2
Molecular classification
Receptor, Serine/threonine-protein kinase, Transforming growth factor beta receptor family
01

Overview

Bone morphogenetic protein receptor type 2 (BMPR2) is a critical transmembrane serine/threonine kinase belonging to the transforming growth factor-beta (TGF-beta) receptor superfamily [UniProt: P41594]. It functions by binding bone morphogenetic proteins (BMPs), which induces the formation of a heteromeric signaling complex with type I receptors to activate downstream SMAD1/5/8 transcription factors. This signaling pathway is essential for maintaining vascular homeostasis, specifically by regulating the proliferation, survival, and apoptosis of pulmonary artery smooth muscle and endothelial cells. Mutations in the BMPR2 gene, particularly loss-of-function mutations, are the primary genetic cause of hereditary pulmonary arterial hypertension (PAH), leading to pathological vascular remodeling and increased pulmonary vascular resistance. Beyond its role in the vasculature, BMPR2 is involved in bone development and has been implicated in the progression of various cancers, such as colorectal and prostate cancer, where it often acts as a tumor suppressor. Therapeutic strategies targeting this pathway include the use of ligand traps like sotatercept, which sequester activins and growth differentiation factors to restore the balance between BMP and TGF-beta signaling. Other approaches under investigation include small molecule activators like tacrolimus that enhance residual BMPR2 signaling or gene therapies aimed at restoring receptor expression in the pulmonary vasculature.

Other names
BMPR-IIBone morphogenetic protein receptor type IIPPH1BMR2T-ALK
02

Mechanism of action

Sotatercept acts as a ligand trap for activins and growth differentiation factors, thereby reducing signaling through ActRIIA/B and restoring the balance with the impaired BMPR2 pathway. Tacrolimus (FK506) acts as a small molecule activator that enhances BMPR2-mediated SMAD signaling by binding to FKBP12, which normally inhibits the receptor.

03

Biological functions

Signal transductionCell proliferationApoptosisVascular remodelingBone morphogenesisCell differentiation
04

Disease associations

Pulmonary arterial hypertensionHereditary hemorrhagic telangiectasiaColorectal cancerCardiovascular disease
05

Safety considerations

ErythrocytosisIncreased hemoglobin levelsTelangiectasiaGingival bleedingImmunosuppression (with tacrolimus)
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

BMPR2 germline mutationsPhosphorylated SMAD1/5/8 levelsPulmonary vascular resistance (PVR)NT-proBNP

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Bone morphogenetic protein receptor type 2 (BMPR2) (BMPR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bone morphogenetic protein receptor type 2 (BMPR2) (BMPR2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call